V
Vesalius Therapeutics
AI-driven drug discovery platform identifying novel gene circuit targets to reverse diseases
About Vesalius Therapeutics
Vesalius Therapeutics is a biotechnology startup that is revolutionizing the approach to drug development for common diseases. The company operates in the healthcare and pharmaceutical industry, serving patients suffering from diseases that account for 90% of human illness, including heart failure, high blood pressure, type II diabetes, Alzheimer’s disease, NASH, and obesity.
Vesalius Therapeutics' business model is centered on its proprietary ContinuumDiscovery™ platform. This platform uses data science, artificial intelligence, and machine learning to identify previously unrecognized clinical patterns in patient groups. It then links these patterns to the combined effects of multiple genes, identifying optimal drug targets to reverse the disease in these patient groups. The platform also uses proprietary patient-derived, cell-based experimental models to screen and characterize drug candidates.
The company's approach to treating common diseases is unique in that it does not view these diseases as monolithic. Instead, it recognizes that they are a constellation of multiple genetically and biologically distinct diseases that affect patients differently. This fresh approach to diagnosing and treating common diseases is what sets Vesalius Therapeutics apart in the market.
The company generates revenue by developing and commercializing novel drugs based on the findings from its ContinuumDiscovery™ platform. By identifying and targeting the unique genetic and biological characteristics of common diseases, Vesalius Therapeutics aims to develop more effective treatments, thereby creating value for patients and stakeholders.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2022 | $75M | $300M | Flagship Pioneering | ↗ |
Growth signals
Latest recorded traffic for Vesalius Therapeutics is 2.8K monthly website visits, up 33.3% over the last three months. Vesalius Therapeutics's team declined 10.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vesalius Therapeutics in the Cambridge ecosystem
The Vesalius Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vesalius Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vesalius Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










